Empagliflozin

Overview

Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes. It helps lower blood sugar levels by preventing glucose reabsorption in the kidneys, promoting its excretion.

API suppliers (8)

Suppliers of Empagliflozin backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Zhejiang Huahai Pharmaceutical Co., Ltd.China2 active DMF
• Zydus Lifesciences LimitedIndia2 active DMF
• Biocon LimitedIndia1 active DMF
• OPTIMUS DRUGS PRIVATE LTD1 active DMF
• Biocon LimitedIndia1 active DMF
• OPTIMUS DRUGS PRIVATE LTD1 active DMF
• Macleods Pharmaceuticals Ltd.India1 active DMF
• APITORIA PHARMA PRIVATE LTDIndia1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (2 approved US products), the latest listed US patent on Empagliflozin expires 11 Dec 2034 and exclusivity 20 Dec 2026. Generic API sourcing typically opens up once these lapse.

Therapeutic areas